Table 2.

Prevalence of ESBL, HRMO and multidrug resistance compared with the national prevalence in 2016

	Rotterdam		Netherlands
	E. coli+K. pneumoniatogether (n = 1297)		All Enterobacteriaceae (n = 101,330)
ESBLa	3.6%b		3.1%c
	E. coli(n = 1130)	K. pneumoniae(n = 167)	E. coli(n = 57,948)d	K. pneumoniae(n = 7801)d
HRMOe	5.0%	4.2%	5.0%	5.0%
Multidrug resistancef	3.3%	1.2%	3.0%	2.0%

ESBL Extended spectrum beta-lactamase

HRMO Highly Resistant Microorganisms

^aESBL was determined as resistant to cefotaxime (or ceftriaxone) and/or ceftazidime

^bDetermined for E. coli and K. pneumonia together

^cDetermined for all Enterobacteriaceae

^dAge > 12 years

^eHRMO was defined as resistant to cefotaxime/ceftriaxone and/or ceftazidime as indicator agents for the production of ESBL, or resistant to both fluoroquinolones (ciprofloxacin) and aminoglycosides (gentamycin or tobramycin) in E. coli and K. pneumonia

^fMultidrug resistance was defined as resistant to co-amoxiclav and ciprofloxacin and co-trimoxazole in E. coli and K. pneumoniae